Universal response in the RKO colon cancer cell line to distinct antimitotic therapies
Crossref DOI link: https://doi.org/10.1038/s41598-018-27267-7
Published Online: 2018-06-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Lorz, Alexander
Botesteanu, Dana-Adriana http://orcid.org/0000-0002-5509-8987
Levy, Doron
Text and Data Mining valid from 2018-06-12
Version of Record valid from 2018-06-12
Article History
Received: 21 February 2018
Accepted: 22 May 2018
First Online: 12 June 2018
Competing Interests
: D.-A.B. is an employee of Boehringer Ingelheim. A.L. and D.L. declare no competing interests.